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preoperative risk factors excluded any additional predictive 
ability of CT even in the high-risk group (P 0.40). These 
data are confirmed by ROC curve analysis, showing a low 
AUC of 54 % for CT, compared with 69 % for Partin tables 
and 80 % for Briganti nomogram. BS showed some posi-
tivity in 74 cases, only four of whom progressed, while 49 
patients with negative BS progressed during their follow-
up, six of them immediately after surgery.
Conclusions According to our opinion, the role of CT and 
BS should be restricted to selected high-risk patients, while 
clinical predictive nomograms should be adopted for the 
surgical planning.
Keywords Prostate cancer · CT · Bone scintigraphy · 
Staging · Accuracy · Lymph node · Metastasis
Introduction
Prostate cancer (PCa) is the most common cancer in men 
and the second most common cause of death from tumors 
in the male population [1]. With the beginning of the 
PSA era, the early diagnosis of PCa has been made pos-
sible, widening the opportunities for local radical therapies 
such as RP or radiation therapy (RT). However, the sce-
nario changes when PCa spreads to the lymph nodes or to 
the bone, becoming a systemic disease: In these cases, the 
opportunity window for a radical therapy is lost, although 
surgery and radiotherapy are progressively achieving a 
role in selected N + PCa patients [2–4]. A correct stag-
ing is therefore essential to properly focus the disease we 
are dealing with, and consequentially to decide the most 
appropriate treatment. Nowadays, computed tomography 
(CT) and bone scintigraphy (BS) are the imaging exami-
nations commonly used in PCa for staging nodal and bone 
Abstract 
Purpose According to the current guidelines, computed 
tomography (CT) and bone scintigraphy (BS) are optional 
in intermediate-risk and recommended in high-risk prostate 
cancer (PCa). We wonder whether it is time for these exam-
inations to be dismissed, evaluating their staging accuracy 
in a large cohort of radical prostatectomy (RP) patients.
Methods To evaluate the ability of CT to predict lymph 
node involvement (LNI), we included 1091 patients treated 
with RP and pelvic lymph node dissection, previously 
staged with abdomino-pelvic CT. As for bone metastases, 
we included 1145 PCa patients deemed fit for surgery, pre-
viously staged with Tc-99m methylene diphosphonate pla-
nar BS.
Results CT scan showed a sensitivity and specificity in 
predicting LNI of 8.8 and 98 %; subgroup analysis dis-
closed a significant association only for the high-risk sub-
group of 334 patients (P 0.009) with a sensitivity of 11.8 % 
and positive predictive value (PPV) of 44.4 %. How-
ever, logistic multivariate regression analysis including 
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involvement, respectively. According to the current guide-
lines, these examinations are optional in intermediate-risk 
and recommended in high-risk PCa [5, 6]. However, their 
use has been questioned by several studies reporting a lim-
ited staging ability for both the procedures. In particular, 
BS is deeply influenced by PSA level and Gleason score 
[7], while the accuracy of CT scan has been shown to be 
really poor, even in those patients with a very high risk of 
nodal metastases [8]. Recently, whole-body magnetic reso-
nance imaging (MRI) was shown to be more sensitive and 
specific than the combination of BS, targeted radiographs 
and abdomino-pelvic CT [9, 10], suggesting an “all-in-one” 
staging approach. Preoperative clinical models, such as 
Partin [11] or Briganti nomograms [12], have been adopted 
in the preoperative risk assessment of PCa for lymph node 
involvement (LNI), and showed possibly more appropriate 
and accurate than CT itself to decide for the need of pel-
vic lymph node dissection (PLND). All these things con-
sidered, we wonder whether it is time for BS and CT to be 
dismissed, or if they still have a role in the PCa staging. We 
tried to find an answer by evaluating their accuracy as stag-
ing examinations in a large cohort of RP patients.
Materials and methods
Patient population
Under institutional review board supervision, data from 
men who underwent RP between 1999 and 2012 with at 
least 2-year follow-up available (PSA records and clini-
cal visits) at thirteen Italian Urology Departments located 
in Piedmont and Aosta Valley Italian regions were com-
bined into the EUREKA-1 database. EUREKA-1 is an 
observational, multicentric, retrospectively derived dataset 
promoted by the CHIC project (sponsored by the Euro-
pean Union, 7th Framework Program, grant agreement no. 
600841); it was approved by the Ethical Committee of 
FPO-IRCCS Cancer Center of Candiolo in July 2013 and 
amended in November 2014; data collected in EUREKA-1 
included socio-demographic parameters, clinical tumor 
characteristics, surgery features, pathology, therapies, clini-
cal and PSA follow-ups, and clinical outcomes.
To evaluate the ability of CT to predict LNI, we included 
1091 patients treated with RP and PLND. All the patients 
were staged before surgery with abdomino-pelvic contrast-
enhanced CT scan; CT was considered positive for LNI if 
at least one node had a short-axis diameter ≥10 mm [8]. 
CT technology greatly varied during the 14-year-long 
period under study. The CT devices used were: Philips 
Tomoscan AV (single detector row), Elscint Twin (2 slices), 
Philips Brilliance (6 slices), Toshiba Aquilion (16 slices), 
Philips Brilliance (40 slices), Philips Brilliance (64 slices), 
GE Discovery (64 slices), with slice thickness ranging in 
between 7 and 2 mm.
Following RP and PLND, the resected nodes were 
deemed positive for LNI if PCa metastases were found at 
the pathology examination (i.e., macro-metastases ≥2 mm 
or micro-metastases <2 mm [13]); finally, pathologic 
results were compared with CT findings.
Besides, patients were stratified according to the 
D’Amico clinical (preoperative) risk classification in low-, 
intermediate- and high-risk groups [14].
As for bone metastases, we included 1145 PCa patients 
scheduled for surgery, staged with planar total-body Tc-
99m methylene diphosphonate BS. Most of the patients 
with positive or equivocal findings underwent targeted 
X-rays or MRI for confirmation. We looked only for 
false-positive and false-negative rates, considering that all 
patients successively underwent surgery.
Standard follow-up included PSA dosage and DRE 
every 3 months for 2 years, every 6 months until the fifth 
year and annually thereafter. Patients with clinical and/or 
serological suspect of bone metastasis at follow-up (i.e., 
fast severe arousal of post-prostatectomy PSA or clinical 
symptoms) underwent BS (and/or CT and/or MRI look-
ing for osteoblastic metastases or secondary fractures) for 
radiologic confirmation.
Statistical analysis
Sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV) were tested, and related P 
values were calculated with Chi-square test. Discrimination 
accuracy was assessed using the C-statistics of the ROC 
area under the curve (AUC). The overall accuracy of Partin 
and Briganti nomograms for LNI was assessed too. Uni-
variate and multivariate logistic regression analyses tested 
the relationships between CT findings and LNI. Covariates 
consisted of preoperative PSA, clinical stage and bioptic 
Gleason score.
P values were considered statistically significant if 
<0.05. All statistical analyses were performed using SAS 
Foundation 9.3 (SAS Institute, Cary, NC, USA).
Results
The characteristics of the 1091 CT-staged patients are 
listed in Table 1. Overall, LNI was detected in 102 patients 
(9.3 %). CT scan was suggestive of LNI in 29 patients 
(2.7 %); of them, only 9 (31 %) had histologically proven 
LNI at PLND. False positives were found in 20 patients 
and false negatives in 93. Sensitivity (Se), specificity (Sp), 
PPV and NPV in predicting LNI for the whole cohort were 
8.8, 98.0, 31.0 and 91.2 %, respectively.
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Subgroup analysis disclosed a significant association 
only for the high-risk subgroup of 334 patients (P 0.009) 
with a Se 11.8 %, Sp 96.2 %, PPV 44.4 % and NPV 81.0 % 
(Table 2).
Of consequence, we further compared the CT predictive 
ability with clinical risk factors in the high-risk group only. 
Logistic multivariate regression analysis including CT 
finding and PSA value, bioptic Gleason score and clinical 
staging left out any significant additional predictive ability 
of CT (P value of 0.40; see Table 3). These data were fur-
ther confirmed by AUC analysis of the ROC curves in the 
high-risk group, showing a low overall accuracy of 54 % 
for CT, compared with 69 % for Partin tables and 80 % for 
Briganti nomogram (Fig. 1).
Regarding BS, patients’ features are given in Table 4. BS 
was performed in 1145 patients (192 low-risk, 567 interme-
diate-risk and 386 high-risk), deemed fit for surgery after 
clinical and/or further radiologic examinations (targeted 
X-rays or MRI). Among them, BS showed some positivity 
in 74 cases; only four of them developed bone metastases 
successively, after an average of 27.5 months from surgery 
(PPV 5.4 %). Finally, 49 patients with negative scintig-
raphy developed bone metastases during their follow-up 
(NPV 95.4 %), six of them within 6 months after surgery.
Discussion
Historically, abdomino-pelvic CT scan and BS played an 
important role as staging procedures in PCa patients, to 
rule out any extra-prostatic presence of disease. As the risk 
of nodal or bone metastases has been associated with bad 
clinical features such as elevated PSA, high clinical stage 
and poor tumor differentiation, CT and BS use has been 
confined to the cases at higher risk, namely some of the 
intermediate-risk and all of the high-risk PCa [5, 7, 11–15]. 
In the last years, however, their role has been strongly ques-
tioned, as a poor staging ability has been demonstrated for 
both procedures [7–10, 16, 17]. Nevertheless, despite the 
criticism of the scientific community, the last EAU guide-
lines still recommend both CT and scintigraphy perfor-
mance for selected groups of PCa patients [5]. Following 
the lead of previous studies [7, 8, 16], we therefore decided 
to assess the usefulness of these examinations as predic-
tors of LNI/bone metastases in our retrospective series of 
patients collected in the Eureka-1 database.
In 2008, a comprehensive meta-analysis on 1024 
patients warned about the poor performance of presurgi-
cal CT in the detection of lymph node metastases: Pooled 
sensitivity and specificity were 0.42 and 0.82, respectively. 
The authors discredited the use of CT, concluding that it 
misrepresented the true nodal metastases involvement, thus 
misdirecting the therapeutic strategies offered to the patient 
[16]. Another study focusing on patients at high-risk of 
locally advanced disease had already shown a low accuracy 
of CT even in this high-risk group, with consequences on 
the correct treatment choice [17]. More recently, Briganti 
et al. [8] evaluated a single-center, homogeneous series of 
1541 patients undergoing RP and extended PLND, all pre-
operatively staged with CT scan. Including only patients 
Table 1  Descriptive characteristics of our series of 1091 patients 
staged with CT split according to D’Amico risk categories
Variables Low risk Intermediate risk High risk
No of patients (%) 245 (22.5 %) 512 (47 %) 334 (30.5 %)
Age (years)
 Mean (SD) 64.2 (6.1) 65.2 (5.7) 65.4 (6.3)
 Median 65 66 66
 Range 49–77 48–79 44–76
PSA (ng/ml)
 Mean (SD) 6.3 (1.8) 10.1 (4.4) 22.5 (22.4)
 Median 6.2 9.9 19
 Range 1–9.9 1.2–20 1.3–196
Clinical tumor stage (%)
 cT1 89 % 62 % 31 %
 cT2 11 % 38 % 44 %
 cT3 – – 25 %
Bioptic Gleason score (%)
 ≤6 100 29 16
 7 – 71 22
 ≥8 – – 62
Percent of positive cores (%)
 Mean (SD) 29.5 (18.4 %) 38 (22.7 %) 45 (26.4 %)
 Median 25 33 41.5
 Range 5–100 5–100 5–100
Lymph nodes removed (no)
 Mean (SD) 14 (9.5) 12.5 (8.5) 13.5 (8.5)
 Median 13 12 12
 Range 1–51 1–59 1–49
CT scan findings [no (%)]
 Negative 245 (100) 501 (98) 316 (94.5)
 Positive 0 (0) 11 (2) 18 (5.5)
Pathologic GS (%)
 ≤6 69 20 9
 7 30 68 39
 ≥8 1 12 52
pT (%)
 pT2 89 67.5 42.5
 pT3 11 31.5 55.5
 pT4 0 1 2
pN [no (%)]
 Negative 244 (99.5 %) 479 (93.5 %) 266 (79.5 %)
 Positive 1 (0.5 %) 33 (6.5 %) 68 (20.5 %)
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who received a standardized anatomically defined PLND, 
their study overcame the false-negative results due to a 
limited PLND. According to their results, sensitivity, spec-
ificity and accuracy of CT scan were 13, 96 and 54.6 %, 
respectively. Again, their conclusions deposed against the 
use of CT scan to decide on the need for, or extent of PLND 
in patients with PCa. In our analysis, the performance of 
CT was confirmed to be very poor, with low sensitivity and 
accuracy of 11.8 and 54 % even in the high-risk group.
The limited sensitivity of CT is due to its inability in 
detecting micro-metastases: A threshold of 10 mm in the 
short-axis nodal diameter for oval nodes and 8 mm for 
round nodes are used as criteria for the diagnosis of lymph 
node metastases [18], but such accuracy is obviously far 
inadequate to detect smaller metastases. On the contrary, 
the risk of false positives due to reactive lymph nodes needs 
to be taken into account, considering the 20 false-positive 
cases in our series.
To overcome the limitations of the available imaging 
techniques, several nomograms or predictive models have 
been proposed to assess the risk of LNI, such as Briganti 
or Partin tools [11, 12]. Both these nomograms have shown 
a very high accuracy for the LNI prediction (up to 88 %), 
and they are currently an important input for the decision-
making process driving the choice to perform PLND. It 
has already been suggested that such preoperative clinical 
models should completely replace the imaging procedures 
in the assessment of the risk of LNI [8]. Interestingly, our 
study confirmed in the high-risk cohort a good discrimina-
tion accuracy for Briganti nomogram (80 %), but not so 
high for Partin model (69 %).
Maybe, the imaging predictive capability will improve 
with the progressive replacement of CT by multiparametric 
MRI, which is the gold standard for prostate imaging, and 
of planar BS with the more specific SPECT–CT BS [19]. 
However, CT and MRI performances are currently similarly 
poor compared with histologic diagnosis [20], even if soon 
iron oxide particles should enhance the detection of enlarged 
lymph nodes [10, 21]. Up to date, choline PET and PET–CT 
have also provided low sensitivity (49.2 %) in the detection of 
lymph node metastases prior to surgery in PCa patients [22].
As for bone metastases detection, the sensitivity of BS 
completed with targeted X-rays has been shown to be 86 %, 
with a 98 % specificity [10]. According to a recently devel-
oped prognostic tool, staging bone scans might be consid-
ered only for patients with a biopsy Gleason score >7, or 
with a PSA > 10 ng/ml and palpable disease (cT2/T3) prior 
to treatment. Such an approach would avoid the use of stag-
ing bone scans in about 81 % of the patients with a NPV 
of 99.6 % [23]. On the basis of these results, the recent 
guidelines recommend bone scan in asymptomatic patients 
only if the PSA level >10 ng/ml or Gleason score ≥8 or 
clinical stage ≥T3, namely the intermediate- and high-
risk situation [5, 6]. However, even if the indications are 
restricted accordingly, a considerable number of performed 
bone scans are unnecessary. In our analysis, we could not 
evaluate the sensitivity and specificity of bone scan, as our 
cohort was composed of patients deemed fit to undergo RP, 
and so excluding all the patients positive to bone scan and 
treated primarily with medical therapy, i.e., androgen dep-
rivation therapy. Nevertheless, we thought interesting to 
report the low accuracy of BS in our series, where 74 cases 
initially found positive were successively cleared for sur-
gery, whereas six cases already harboring bone metastases 
were not detected.
Table 2  Cross-tabulation and measure of association (Chi-square 
test) between CT finding and LNI at PLND split according to risk 
categories
Stat parameters  
(%)
P value
Low risk pN NEG pN POS NPV 99.6 1.00
 CT NEG 244 1 PPV 0
 CT POS 0 0 Sensitivity 0
Specificity 100
Intermediate risk pN NEG pN POS NPV 93.6 0.72
 CT NEG 469 32 PPV 9.1
 CT POS 10 1 Sensitivity 3.0
Specificity 97.9
High risk pN NEG pN POS NPV 81.0 0.009
 CT NEG 256 60 PPV 44.4
 CT POS 10 8 Sensitivity 11.8
Specificity 96.2
Overall pN NEG pN POS NPV 91.2 <0.001
 CT NEG 969 93 PPV 31.0
 CT POS 20 9 Sensitivity 8.8
Specificity 98.0
Table 3  Univariate and multivariate logistic regression in the high-
risk group (N = 334) including CT finding, PSA, bioptic Gleason 
score and clinical stage (A), Partin tables (B) and Briganti nomogram 
(C)
P value—univariate 
analysis
P value—multivariate 
analysis
(A)
 PSA <0.001 <0.001
 cT <0.001 0.01
 bGS 0.03 0.04
 CT finding 0.01 0.40
(B)
 Partin tables 0.001
(C)
 Briganti nomogram <0.001
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Fig. 1  Area under the curve 
of the ROC graph in high-risk 
patients: CT finding, 54 % (a); 
Partin tables, 69 % (b) and 
Briganti nomogram, 80 % (c)
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Our study does have several limitations, mainly due to 
the selection criteria of our database, the heterogeneous-
ness of the cohort and the retrospective nature of our data.
The main issue is inherent to our database, consisting in 
a population of men having been deemed fit for surgery; 
this criterion introduces substantial selection bias (i.e., men 
found to harbor metastatic disease and not eligible for RP, 
or who underwent primary RT instead of RP); this trouble 
is more relevant for BS than for CT, and so data collected 
on RP patients are inadequate to perform a proper evalua-
tion of the accuracy of BS. A second limitation regarding 
bone scan is the lack of histologic confirmation from bone 
biopsy specimens; nevertheless, the long follow-up of our 
series allowed us to assess which patients harbored bone 
metastases not discovered during the preoperatory stag-
ing. Furthermore, the staging imaging procedures were 
performed by different physicians and with different equip-
ments without any central review. One final limitation is 
related to the PLND template, which was not anatomically 
defined as recently recommended [8]: after all, the recom-
mendations about the extension of PLND have changed 
several times in the last 15 years. PLND extension and tem-
plate varied significantly between the participating urology 
divisions, while no statistical trend was identified in the 
mean number of nodes resected according to preoperatory 
D’Amico risk class (14 vs. 12.5 vs. 13.5 nodes in low-, 
intermediate- and high-risk classes, respectively). On the 
other hand, our retrospective data provide a snapshot about 
the usefulness of PCa staging examinations in a vast region 
of Italy over a 15-year period.
According to our findings, these examinations have 
only a minor effect on the correct diagnostic and therapeu-
tic strategy. Of consequence, we advise to stage patients 
with CT just if they belong to high-risk category (i.e., 
PSA > 20 ng/ml or GS ≥ 8 or clinical stage ≥cT2c) and no 
functional MRI or CT–PET scan is available; this result is 
in agreement with AUA recommendations recently reported 
by Risko et al. [24].
Besides, bone scan too may be considered useful in the 
high-risk group only, so to decrease in lower-risk classes 
the incidence of misleading false-positive examinations, 
which can hamper or delay the choice of a radical therapy. 
In addition, a negative impact of a widespread use of these 
radiologic examinations on healthcare costs should be 
taken into account.
Conclusions
Our study confirms the poor accuracy of CT scan and BS 
as staging examinations for PCa. Their role should be 
restricted to selected high-risk cases, whereas their avoid-
ance as routine examinations would simplify the diagnostic 
work-flow and save resources and money for the National 
Health Systems. As previously suggested in the literature, 
clinical predictive nomograms about lymph node involve-
ment are more reliable to plan the best surgical therapeutic 
strategy.
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Table 4  Descriptive characteristics of our series of 1145 patients 
staged with BS split according to D’Amico risk categories
Variables Low risk Intermediate risk High risk
No of patients (%) 192 (17 %) 567 (49.5 %) 386 (33.5 %)
Age (years)
 Mean (SD) 64.4 (6.0) 65.0 (5.8) 65.6 (6.2)
 Median 65 65 66
 Range 50–77 48–79 44–76
PSA (ng/ml)
 Mean (SD) 6.3 (1.9) 10.6 (4.4) 22.0 (21.9)
 Median 6.2 10.2 18
 Range 1–9.7 1.2–20 1.3–196
Clinical tumor stage (%)
 cT1 74 62 33.5
 cT2 26 38 41
 cT3 – – 25.5
Bioptic Gleason score (%)
 ≤6 100 33 17.5
 7 – 67 21.5
 ≥8 – – 61
Percent of positive cores (%)
 Mean (SD) 31.0 (18.3) 39.1 (23.2) 44.9 (26.4)
 Median 26.8 35.7 41.7
 Range 5–100 5–100 5–100
BS findings [no (%)]
 Negative 182 (95) 540 (95) 349 (90)
 Positive 10 (5) 27 (5) 37 (10)
Pathologic GS (%)
 ≤6 56 21 8.5
 7 40 66 40.5
 ≥8 4 13 51
pT (%)
 pT2 80 64 42.5
 pT3 20 35 55.5
 pT4 0 1 2
Bone progression at FU [no (%)]
 Negative 190 (99) 548 (96.5) 354 (91.5)
 Positive 2 (1) 19 (3.5) 32 (8.5)
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